)
Genus (GNS) investor relations material
Genus H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
FY 2026 adjusted PBT and adjusted EPS each rose 35%; free cash flow reached £62m, and PIC China’s JV formation strengthened the balance sheet.
Strategic progress included PRP approvals in four additional markets, initial commercialization preparations in Latin America, and a 10% proposed dividend increase plus a £60m buyback.
Financial highlights
Revenue was £658.1m, down 2% in actual currency, primarily reflecting PIC China’s deconsolidation; adjusted PBT rose 35% to £100.2m and adjusted EPS rose 35% to £1.103.
Adjusted operating profit including JVs increased 25% to £116m; margin rose 380 bps to 17.6%, or 350 bps to 16.8% excluding BCA milestones in both years.
Statutory PBT was £310.5m, mainly reflecting a £204.1m gain on deconsolidating PIC China; exceptional expenses fell to £5.8m from £11.4m.
Free cash flow rose to £62m from £40.9m; cash conversion was 94%, supported by higher adjusted EBITDA, increased JV dividends and lower exceptional cash payments.
Outlook and guidance
FY 2027 underlying adjusted PBT in constant currency is expected to be moderately higher year over year than normalized FY 2026 PBT of £90.3m, with growth weighted to H2; group adjusted PBT is expected to be in line with consensus.
Moderate adjusted operating profit growth is anticipated in both PIC and ABS; FY 2027 profit phasing is expected to flip from FY 2026, with North American PIC disease headwinds and Brazil weakness weighing on H1.
FY 2027 free cash flow is expected to remain strong but be lower than FY 2026, reflecting China JV formation, modestly higher capital expenditure and the absence of the FY 2026 BCA milestone.
FY 2027 normalized earnings considerations include annualized ABS VAP phase 3 benefits, higher bovine and porcine product development and PRP costs, and lower average net debt.
ABS continues to target double-digit operating margins over the medium term; FY 2027 research costs are expected to rise but remain below 3% of revenue.
- FY26 profit and cash flow exceeded expectations, with net leverage sharply reduced.GNS
Trading update - Record H1 profit, strong PIC and ABS growth, and major China JV drive positive FY26 outlook.GNS
H1 2026 - Market leadership, innovation in gene editing, and China expansion drive strong growth prospects.GNS
44th Annual J.P. Morgan Healthcare Conference Presentation - Profit outlook raised above expectations after strong H1 and China joint venture progress.GNS
Trading update - Record profit growth, China JV acceleration, and FDA PRP approval drive strong FY25 results.GNS
H2 2025 - Profit growth expected in FY25 after strategic gains and cost savings, despite market challenges.GNS
H2 2024 - Profit fell as China and ABS faced headwinds, but margin and PRP progress continued.GNS
H2 2024 (Q&A) - Profit outlook raised to top end of expectations as both ABS and PIC segments outperform.GNS
Trading Update - Strong H1 profit growth, margin gains, and strategic progress drive a positive outlook.GNS
H1 2025
Next Genus earnings date
Next Genus earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage
)